Cargando…

Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases

Anti-tumor necrosis factor (TNF) antibodies are successfully used in the therapy of inflammatory bowel diseases (IBD). However, the molecular mechanism of action of these agents is still a matter of debate. Apart from neutralization of TNF, influence on the intestinal barrier function, induction of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Billmeier, Ulrike, Dieterich, Walburga, Neurath, Markus F, Atreya, Raja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5107694/ https://www.ncbi.nlm.nih.gov/pubmed/27895418 http://dx.doi.org/10.3748/wjg.v22.i42.9300

Ejemplares similares

Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases
por: Rath, Timo, et al.
Publicado: (2018)

Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn’s disease
por: Schmitt, Heike, et al.
Publicado: (2019)

Endoscopic Therapy in Inflammatory Bowel Diseases
por: Neumann, Helmut, et al.
Publicado: (2015)

Innovative Diagnostic Endoscopy in Inflammatory Bowel Diseases: From High-Definition to Molecular Endoscopy
por: Bojarski, Christian, et al.
Publicado: (2021)

IL-23 Blockade in Anti-TNF Refractory IBD: From Mechanisms to Clinical Reality
por: Atreya, Raja, et al.
Publicado: (2022)

Intestinal ex vivo organoid culture reveals altered programmed crypt stem cells in patients with celiac disease
por: Dieterich, Walburga, et al.
Publicado: (2020)

Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease
por: Lichnog, Charlotte, et al.
Publicado: (2019)

“HIIT the Inflammation”: Comparative Effects of Low-Volume Interval Training and Resistance Exercises on Inflammatory Indices in Obese Metabolic Syndrome Patients Undergoing Caloric Restriction
por: Reljic, Dejan, et al.
Publicado: (2022)

Innate Lymphoid Cells as Regulators of Epithelial Integrity: Therapeutic Implications for Inflammatory Bowel Diseases
por: Schulz-Kuhnt, Anja, et al.
Publicado: (2021)

Personalizing Treatment in IBD: Hype or Reality in 2020? Can We Predict Response to Anti-TNF?
por: Atreya, Raja, et al.
Publicado: (2020)

Anti-tumor necrosis factor therapy in inflammatory bowel disease
por: Ramakrishna, B.S.
Publicado: (2017)

Expression of inflammatory mediators in biofilm samples and clinical association in inflammatory bowel disease patients—a preliminary study
por: Buchbender, Mayte, et al.
Publicado: (2021)

Magnification endoscopy with optical chromoendoscopy shows strong correlation with histologic inflammation in patients with inflammatory bowel disease
por: Klenske, Entcho, et al.
Publicado: (2019)

Mild COVID-19 Symptoms in an Infliximab-Treated Ulcerative Colitis Patient: Can Ongoing Anti-TNF Therapy Protect against the Viral Hyperinflammatory Response and Avoid Aggravated Outcomes?
por: Abdullah, Abdullah, et al.
Publicado: (2020)

The efficacy of immunomodulators in the prevention and suppression of anti-drug antibodies to anti-tumor necrosis factor therapy in inflammatory bowel disease
por: Fousekis, Fotios S., et al.
Publicado: (2022)

Cross-sectional imaging of intestinal barrier dysfunction by confocal laser endomicroscopy can identify patients with food allergy in vivo with high sensitivity
por: Rath, Timo, et al.
Publicado: (2021)

Functional Molecular Network Analysis Enables Prediction of Response to Vedolizumab Therapy in Anti-TNF Refractory IBD Patients
por: Breidert, Matthias, et al.
Publicado: (2020)

Deciphering Novel Mechanistic and Pharmacokinetic Effects of Tofacitinib in Intestinal Inflammation: Expect the Unexpected
por: Atreya, Raja, et al.
Publicado: (2021)

Strategies for overcoming anti-tumor necrosis factor drug antibodies in inflammatory bowel disease: Case series and review of literature
por: Kothari, Mansi M, et al.
Publicado: (2017)

Novel Pharmacological Therapy in Inflammatory Bowel Diseases: Beyond Anti-Tumor Necrosis Factor
por: Pagnini, Cristiano, et al.
Publicado: (2019)

Can Anti-Tumor Necrosis Factor Agents Be Discontinued in Patients with Inflammatory Bowel Disease?
por: Park, Jihye, et al.
Publicado: (2021)

Exit strategies in inflammatory bowel disease: Looking beyond anti-tumor necrosis factors
por: Crispino, Federica, et al.
Publicado: (2023)

The TLR9 Agonist Cobitolimod Induces IL10-Producing Wound Healing Macrophages and Regulatory T Cells in Ulcerative Colitis
por: Schmitt, Heike, et al.
Publicado: (2020)

How the Tumor Micromilieu Modulates the Recruitment and Activation of Colorectal Cancer-Infiltrating Lymphocytes
por: Atreya, Imke, et al.
Publicado: (2022)

Role of the IL23/IL17 Pathway in Crohn’s Disease
por: Schmitt, Heike, et al.
Publicado: (2021)

Inflammatory Bowel Diseases: Current Medical and Surgical Therapy
por: Neurath, Markus F., et al.
Publicado: (2015)

Fatal infections in older patients with inflammatory bowel disease on anti-tumor necrosis factor therapy
por: Lee, Way-Seah, et al.
Publicado: (2017)

Association of Anti–Tumor Necrosis Factor Therapy With Mortality Among Veterans With Inflammatory Bowel Disease
por: Cohen-Mekelburg, Shirley, et al.
Publicado: (2021)

Beyond endoscopic assessment in inflammatory bowel disease: real-time histology of disease activity by non-linear multimodal imaging
por: Chernavskaia, Olga, et al.
Publicado: (2016)

Food Intolerance of Unknown Origin: Caused by Mucosal Inflammation? A Pilot Study
por: Dieterich, Walburga, et al.
Publicado: (2021)

Feasibility, Safety, and Preliminary Efficacy of Very Low-Volume Interval Training in Advanced Cancer Patients
por: RELJIC, DEJAN, et al.
Publicado: (2022)

The outcome of patients with inflammatory bowel disease–associated colorectal cancer is not worse than that of patients with sporadic colorectal cancer–a matched-pair analysis of survival
por: Vitali, Francesco, et al.
Publicado: (2021)

Dynamic, Transient, and Robust Increase in the Innervation of the Inflamed Mucosa in Inflammatory Bowel Diseases
por: Gonzalez Acera, Miguel, et al.
Publicado: (2021)

Inflammatory Bowel Diseases: Current Medical and Surgical Therapy
por: Lamprecht, Georg, et al.
Publicado: (2015)

Study of tumor necrosis factor receptor in the inflammatory bowel disease
por: Souza, Roberta Figueiroa, et al.
Publicado: (2023)

Reversal of Immunogenicity in Pediatric Inflammatory Bowel Disease Patients Receiving Anti-Tumor Necrosis Factor Medications
por: Kang, Elise, et al.
Publicado: (2018)

Factors Associated with the Immunogenicity of Anti-Tumor Necrosis Factor Agents in Pediatric Patients with Inflammatory Bowel Disease
por: Kim, Ju Young, et al.
Publicado: (2021)

Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease
por: Marsal, Jan, et al.
Publicado: (2022)

Impact of thiopurine dose in anti-tumor necrosis factor combination therapy on outcomes in inflammatory bowel disease
por: Nawaz, Ahmad, et al.
Publicado: (2023)

Serum anti-glycan-antibodies in relatives of patients with inflammatory bowel disease
por: Kamm, Florian, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ltnchb8ma8men09br588b21c80